Search

IMI2 Call for Research Proposals

The indicative budget for this topic is 40 million Euro, half of which by way of an in kind contribution from Industry Consortium EFPIA (European Federation of Pharmaceutical Industries and Associations) companies.

Read more

How to apply for TRTH

Download the letter of intent template.  Fill in the template and get it duly signed. When you are ready, access the EHA Portal at http://eha. fluxx. io. and register yourself by clicking on the ‘Create an Account’ button.

Read more

How to apply for CBTH

TimelinesApplication CBTH 2025
Deadline: September 24, 2024 (15:00 CEST)

Notification
November 2024

How to apply?Download the signature letter template. Fill in the template and get it duly signed for upload into the online application platform.

Read more

Immune Therapies for Hematologic Disorders

Recently the treatment of hematological and solid malignancies has been revolutionized by the introduction of novel immunotherapeutic strategies.

Read more

EU funding calls for hematology

Horizon Europe
European partnership for pandemic preparedness (November 26, 2024)
Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD) (deadline: November 26, 2024)
MSCA Doctoral Networks 2024 (deadline: November 27, 2024)
MSCA…

Read more

Research training documents for scholars

CBTH documentsCBTH Non-disclosure Agreement

CRTH documentsCRTH Conditions of Acceptance and Participation

CRTH Non-disclosure Agreement

TRTH documentsTRTH Non-disclosure Agreement

Read more

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

These Guidelines were developed by the European Hematology Association (EHA) and European Society for Medical Oncology (ESMO). The 2 societies nominated authors to write the guidelines as well as reviewers to comment on them.

Read more

Expert opinions for specific hematologic malignancies

Expert opinions for specific hematologic malignancies



Read more